Independent association of HbA1c and nonalcoholic fatty liver disease in an elderly Chinese population

BMC Gastroenterology

Volumn 13, Issue 1, 2013, Pages

  Ma, Han ^a   Xu, Chengfu ^a   Xu, Lei ^a,b   Yu, Chaohui ^a   Miao, Min ^c   Li, Youming ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b NINGBO FIRST HOSPITAL   (China)

^c Zhenhai Lianhua Hospital   (China)

Author keywords

Elderly; Fatty liver; Glycosylated hemoglobin; Obesity

Indexed keywords

HEMOGLOBIN A1C;

AGED; ARTICLE; CHINA; CHINESE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; EMPLOYEE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PENSIONER; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; REFERENCE VALUE; RISK ASSESSMENT;

AGED; BLOOD GLUCOSE; CHINA; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LOGISTIC MODELS; MALE; PREVALENCE; RISK FACTORS;

EID: 84871911695     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-13-3     Document Type: Article

References (34)

1. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009, 50(1):204-210. 10.1016/j.jhep.2008.10.010, 19014878.
2. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140(1):124-131. 10.1053/j.gastro.2010.09.038, 20858492.
3. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(S1):S99-S112. 10.1002/hep.20973, 16447287.
4. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129(1):113-121. 10.1053/j.gastro.2005.04.014, 16012941.
5. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005, 143(10):722-728.
6. Ryan MC, Wilson AM, Slavin J, Best JD, Jenkins AJ, Desmond PV. Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care 2005, 28(5):1222-1224. 10.2337/diacare.28.5.1222, 15855597.
7. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999, 84(5):1513-1517. 10.1210/jc.84.5.1513, 10323371.
8. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, Wasada T. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005, 22(9):1141-1145. 10.1111/j.1464-5491.2005.01582.x, 16108839.
9. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2011, 34(Suppl 1):62-69. American Diabetes Association.
10. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40(6):1387-1395. 10.1002/hep.20466, 15565570.
11. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006, 26(7):856-863. 10.1111/j.1478-3231.2006.01311.x, 16911469.
12. Koehler EM, Schouten JN, Hansen BE, van Rooij FJ, Hofman A, Stricker BH, Janssen HL. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol 2012, .
13. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30(6):1356-1362. 10.1002/hep.510300604, 10573511.
14. Bae JC, Cho YK, Lee WY, Seo HI, Rhee EJ, Park SE, Park CY, Oh KW, Sung KC, Kim BI. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol 2010, 105(11):2389-2395. 10.1038/ajg.2010.275, 20628364.
15. Davidson MB, Schriger DL. Effect of age and race/ethnicity on HbA1c levels in people without known diabetes mellitus: implications for the diagnosis of diabetes. Diabetes Res Clin Pract 2010, 87(3):415-421. 10.1016/j.diabres.2009.12.013, 20061043.
16. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 2009, 50(5):1029-1034. 10.1016/j.jhep.2008.11.021, 19299029.
17. Xu C, Xu L, Yu C, Miao M, Li Y. Association between thyroid function and nonalcoholic fatty liver disease in euthyroid elderly Chinese. Clin Endocrinol (Oxf) 2011, 75(2):240-246.
18. Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166). J Dig Dis 2011, 12(1):38-44. 10.1111/j.1751-2980.2010.00476.x, 21276207.
19. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006, 23(5):469-480. 10.1111/j.1464-5491.2006.01858.x, 16681555.
20. Yki-Järvinen H. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes. Dig Dis 2010, 28(1):203-209. 10.1159/000282087, 20460912.
21. D'Adamo E, Giannini C, Chiavaroli V, de Giorgis T, Verrotti A, Chiarelli F, Mohn A. What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children?. Antioxid Redox Signal 2011, 14(6):1167-1172. 10.1089/ars.2010.3719, 20969485.
22. Bian H, Yan H, Zeng M, Rao S, Yao X, Zhou J, Jia W, Gao X. Increased liver fat content and unfavorable glucose profiles in subjects without diabetes. Diabetes Technol Ther 2011, 13(2):149-155. 10.1089/dia.2010.0101, 21284482.
23. Yki-Jarvinen H, Westerbacka J. The fatty liver and insulin resistance. Curr Mol Med 2005, 5(3):287-295. 10.2174/1566524053766031, 15892648.
24. Higgins PJ, Garlick RL, Bunn HF. Glycosylated hemoglobin in human and animal red cells: role of glucose permeability. Diabetes 1982, 31(9):743-748. 10.2337/diabetes.31.9.743, 7160543.
25. Khera PK, Joiner CH, Carruthers A, Lindsell CJ, Smith EP, Franco RS, Holmes YR, Cohen RM. Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes 2008, 57(9):2445-2452. 10.2337/db07-1820, 2518496, 18591386.
26. Mantena SK, King AL, Andringa KK, Eccleston HB, Bailey SM. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med 2008, 44(7):1259-1272. 10.1016/j.freeradbiomed.2007.12.029, 2323912, 18242193.
27. Otogawa K, Kinoshita K, Fujii H, Sakabe M, Shiga R, Nakatani K, Ikeda K, Nakajima Y, Ikura Y, Ueda M, et al. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. Am J Pathol 2007, 170(3):967-980. 10.2353/ajpath.2007.060441, 1864892, 17322381.
28. Cazzola R, Rondanelli M, Russo-Volpe S, Ferrari E, Cestaro B. Decreased membrane fluidity and altered susceptibility to peroxidation and lipid composition in overweight and obese female erythrocytes. J Lipid Res 2004, 45(10):1846-1851. 10.1194/jlr.M300509-JLR200, 15231850.
29. Reeder BJ. The redox activity of hemoglobins: from physiologic functions to pathologic mechanisms. Antioxid Redox Signal 2010, 13(7):1087-1123. 10.1089/ars.2009.2974, 20170402.
30. Kung CM, Tseng ZL, Wang HL. Erythrocyte fragility increases with level of glycosylated hemoglobin in type 2 diabetic patients. Clin Hemorheol Microcirc 2009, 43(4):345-351.
31. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007, 191(2):235. 10.1016/j.atherosclerosis.2006.08.021, 16970951.
32. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. Diabetologia 2008, 51(11):1947-1953. 10.1007/s00125-008-1135-4, 18762907.
33. Adams RJ, Appleton SL, Hill CL, Wilson DH, Taylor AW, Chittleborough CR, Gill TK, Ruffin RE. Independent association of HbA(1c) and incident cardiovascular disease in people without diabetes. Obesity (Silver Spring) 2009, 17(3):559-563.
34. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010, 362(9):800-811. 10.1056/NEJMoa0908359, 2872990, 20200384.